1. Elevated neutrophil-to-lymphocyte ratio predicts poor outcome in patients with advanced non-small-cell lung cancer receiving first-line gefitinib or erlotinib treatment.
- Author
-
Lin, Gui‐Nan, Peng, Jie‐Wen, Liu, Pan‐Pan, Liu, Dong‐Ying, Xiao, Jian‐jun, and Chen, Xiao‐Qin
- Subjects
- *
LYMPHOCYTES , *NEUTROPHILS , *HEALTH outcome assessment , *EPIDERMAL growth factor receptors , *GEFITINIB , *ERLOTINIB , *NON-small-cell lung carcinoma , *PATIENTS , *PROGNOSIS - Abstract
Aim Elevated neutrophil-to-lymphocyte ratio ( NLR) has been demonstrated to be a poor prognostic factor in multiple types of malignancies, whereas the effect of NLR on the prognosis of epidermal growth factor receptor ( EGFR)-mutated advanced non-small-cell lung cancer ( NSCLC) patients treated with first-line EGFR tyrosine kinase inhibitors ( TKIs) is not fully addressed. Methods 81 metastatic NSCLC patients harboring EGFR mutation treated with first-line EGFR TKIs were retrospectively included. The associations between baseline clinical characteristics, including NLR, and tumor response, progression and survival were investigated. Results Elevated NLR (≥3.5) was observed in 33 of 81 patients. The progression-free and overall survival of the patients with increased NLR was significantly worse than that of the patients with decreased NLR (8.20 vs 10.60 months, P < 0.001 and 17.20 vs 23.20 months, P < 0.001, respectively). Elevated NLR was confirmed to be an independent prognostic factor for worse progression-free and overall survival in Cox multivariate analysis. Conclusion Elevated NLR is likely to be associated with poor outcome in EGFR-mutated advanced NSCLC patients treated with first-line EGFR TKIs. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF